MA46342A - Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation - Google Patents
Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisationInfo
- Publication number
- MA46342A MA46342A MA046342A MA46342A MA46342A MA 46342 A MA46342 A MA 46342A MA 046342 A MA046342 A MA 046342A MA 46342 A MA46342 A MA 46342A MA 46342 A MA46342 A MA 46342A
- Authority
- MA
- Morocco
- Prior art keywords
- mglur2
- pharmaceutically acceptable
- compositions
- compounds
- isochroman
- Prior art date
Links
- VZWXIQHBIQLMPN-UHFFFAOYSA-N chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 title abstract 2
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 229940126662 negative allosteric modulator Drugs 0.000 title abstract 2
- SFLGSKRGOWRGBR-UHFFFAOYSA-N phthalane Chemical class C1=CC=C2COCC2=C1 SFLGSKRGOWRGBR-UHFFFAOYSA-N 0.000 title abstract 2
- 101150016175 Grm2 gene Proteins 0.000 title 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000010877 cognitive disease Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 208000027520 Somatoform disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
- 208000027753 pain disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000022925 sleep disturbance Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne certains composés de chromane, d'isochromane et de dihydroisobenzofurane substitués de formule (i) ou un sel pharmaceutiquement acceptable de celui-ci, le cycle a étant un fragment choisi parmi (ii), (iii), (iv) et (v), et le cycle b, n, r1, r2, r2a, r3, et r3a sont tels que définis dans la description. Les composés de l'invention sont utiles en tant qu'inhibiteurs de mglur2, ou modulateurs allostériques négatifs de mglur2 (nams), et dans des méthodes de traitement d'un patient pour des maladies ou des troubles dans lesquels le récepteur mglur2-nam est impliqué, tels que la maladie d'alzheimer, le déficit cognitif, le déficit cognitif léger, la schizophrénie ou autres troubles de l'humeur, troubles de la douleur et troubles du sommeil, par l'administration au patient d'une quantité thérapeutiquement efficace d'un composé de l'invention ou d'un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également des compositions pharmaceutiques comprenant un composé de l'invention ou un sel pharmaceutiquement acceptable de celui-ci (facultativement en combinaison avec un ou plusieurs principes actifs supplémentaires) et un support pharmaceutiquement acceptable, et l'utilisation des composés et compositions pharmaceutiques de l'invention dans le traitement de telles maladies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400150P | 2016-09-27 | 2016-09-27 | |
| PCT/US2017/053155 WO2018063955A1 (fr) | 2016-09-27 | 2017-09-25 | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46342A true MA46342A (fr) | 2019-08-07 |
| MA46342B1 MA46342B1 (fr) | 2021-05-31 |
Family
ID=60043302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46342A MA46342B1 (fr) | 2016-09-27 | 2017-09-25 | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10335399B2 (fr) |
| EP (1) | EP3519416B1 (fr) |
| JP (3) | JP6681517B2 (fr) |
| KR (1) | KR102296043B1 (fr) |
| CN (1) | CN109983022B (fr) |
| AR (1) | AR109714A1 (fr) |
| AU (2) | AU2017334870C1 (fr) |
| CA (1) | CA3037537C (fr) |
| CL (1) | CL2019000778A1 (fr) |
| CO (1) | CO2019002673A2 (fr) |
| CR (1) | CR20190147A (fr) |
| CY (1) | CY1124346T1 (fr) |
| DK (1) | DK3519416T3 (fr) |
| DO (1) | DOP2019000076A (fr) |
| EA (1) | EA038627B1 (fr) |
| EC (1) | ECSP19020742A (fr) |
| ES (1) | ES2868973T3 (fr) |
| GE (2) | GEP20217279B (fr) |
| HR (1) | HRP20210793T1 (fr) |
| HU (1) | HUE054898T2 (fr) |
| IL (1) | IL265366B (fr) |
| JO (1) | JOP20190058B1 (fr) |
| LT (1) | LT3519416T (fr) |
| MA (1) | MA46342B1 (fr) |
| MD (1) | MD3519416T2 (fr) |
| MX (1) | MX392132B (fr) |
| MY (1) | MY196807A (fr) |
| NI (1) | NI201900025A (fr) |
| PE (1) | PE20190609A1 (fr) |
| PH (1) | PH12019500597B1 (fr) |
| PL (1) | PL3519416T3 (fr) |
| PT (1) | PT3519416T (fr) |
| RS (1) | RS61890B1 (fr) |
| SI (1) | SI3519416T1 (fr) |
| TN (2) | TN2020000160A1 (fr) |
| TW (1) | TWI764934B (fr) |
| UA (1) | UA123687C2 (fr) |
| WO (1) | WO2018063955A1 (fr) |
| ZA (1) | ZA201901701B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3519416T (pt) * | 2016-09-27 | 2021-05-13 | Merck Sharp & Dohme | Derivados de cromano, isocromano e diidroisobenzofurano como moduladores alostericos mglur2-negativos, composições e sua utilização |
| CN117924208A (zh) | 2018-01-19 | 2024-04-26 | 赛特凯恩蒂克公司 | 作为心肌节抑制剂的二氢苯并呋喃和茚类似物 |
| EP3814343B1 (fr) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Inhibiteurs de sarcomères cardiaques |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| JP7291426B2 (ja) * | 2019-03-01 | 2023-06-15 | 山東亨利醫藥科技有限責任公司 | 縮合三環式化合物を調製するための方法、及びその中間体 |
| WO2022187501A1 (fr) | 2021-03-04 | 2022-09-09 | Cytokinetics, Inc. | Inhibiteurs de sarcomes cardiaques |
| WO2023278729A1 (fr) * | 2021-06-30 | 2023-01-05 | The General Hospital Corporation | Ligands d'imagerie à base de chromane |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| WO2005014543A1 (fr) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | Compose a cycle condense utilise comme inhibiteur de la polymerase du vhc |
| CA2624294A1 (fr) | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Quinolines substituees en tant qu'inhibiteurs de la biosynthese de leucotriene |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| EP2326631A4 (fr) | 2008-08-18 | 2012-03-21 | Univ Yale | Modulateurs de mif |
| ES2440001T3 (es) * | 2009-05-12 | 2014-01-27 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos |
| US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| CA2853923A1 (fr) | 2011-11-03 | 2013-05-10 | Merck Sharp & Dohme Corp. | Derives quinoleine carboxamides et quinoleine carbonitriles en tant que modulateurs allosteriques negatifs de mglur2, compositions et leur utilisation |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2016029454A1 (fr) * | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | Dérivés de tétrahydronaphtyridine comme modulateurs allostériques négatifs de mglur2, compositions et leur utilisation |
| US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| WO2016149324A1 (fr) | 2015-03-16 | 2016-09-22 | Vanderbilt University | Modulateurs allostériques négatifs du récepteur métabotropique du glutamate de type 2 |
| JP6471614B2 (ja) | 2015-05-29 | 2019-02-20 | 株式会社リコー | 通信端末、通信システム、通信制御方法、及びプログラム |
| JP2018154554A (ja) | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
| PT3519416T (pt) * | 2016-09-27 | 2021-05-13 | Merck Sharp & Dohme | Derivados de cromano, isocromano e diidroisobenzofurano como moduladores alostericos mglur2-negativos, composições e sua utilização |
-
2017
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/fr active Active
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en not_active Ceased
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh not_active IP Right Cessation
- 2017-09-25 PH PH1/2019/500597A patent/PH12019500597B1/en unknown
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/fr not_active Ceased
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja not_active Expired - Fee Related
- 2017-09-25 CA CA3037537A patent/CA3037537C/fr active Active
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko not_active Expired - Fee Related
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es active IP Right Grant
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh not_active Expired - Fee Related
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
- 2017-09-25 MX MX2019003492A patent/MX392132B/es unknown
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
-
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja not_active Expired - Fee Related
-
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja not_active Expired - Fee Related
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en not_active Ceased
-
2021
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
-
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA51530B1 (fr) | Composés cycliques fondus | |
| MA42295B1 (fr) | Composés de la benzoxazépin oxazolidinone et procédé pour leur utilisation | |
| MA30411B1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| MA42239B1 (fr) | Nouveaux dérivés d'hydroxyester, leur procédé de préparation et compositions pharmaceutiques les contenant | |
| TNSN04246A1 (fr) | Derives d'heteroarylamides benzocondenses de thienopyridines utiles comme agents therapeutiques, compositions pharmaceutiques les contenant et methodes pour leur utilisation | |
| MA42230B1 (fr) | Dérivés bicycliques, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MA33734B1 (fr) | N1-pyrazolospirocétone inhibitrices d'acétyl-coa carboxylase | |
| MA34898B1 (fr) | Nouveaux dérivés hétérocycliques et leur utilisation dans le traitement de troubles neurologiques | |
| MA42231B1 (fr) | Nouveaux dérivés d'hydroxyacide, leur procédé de préparation, et compositions pharmaceutiques les contenant | |
| MX344308B (es) | Derivados de quinolina carboxamida y quinolina carbonitrilo como moduladores alostericos negativos de mglur2, composiciones y su uso. | |
| TN2013000393A1 (fr) | Derives de la pyrazolospirocetone pour une utilisation comme inhibiteurs de l'acetyl-coa carboxylase | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| MA43639B1 (fr) | Nouveaux dérivés d'ammonium, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant | |
| MA40111B1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA32108B1 (fr) | Derives d'indazole | |
| MA52482B1 (fr) | Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| MA30308B1 (fr) | Dérivés de benzoisoindole utilisés dans le traitement de la douleur | |
| MA33979B1 (fr) | Piperazines en tant qu'agents antipaludiques | |
| CA2151039A1 (fr) | Utilisation de l'idazoxan et ses derives pour la preparation d'un medicament destine au traitement de la maladie de parkinson et de son evolution | |
| MA49910B1 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
| MA50457B1 (fr) | Dérivés de pyridine carbonyle et leurs utilisations thérapeutiques en tant qu'inhibiteurs de trpc6 | |
| MA34196B1 (fr) | Dérivés d'imidazole condensés comme antagonistes de trpv3 |